← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Cognition Therapeutics, Inc.
Pittsburgh, PA
$153,400,583
Total funding
18
Grants
Funding over time
peak $40.7M · FY2010–25$50M$37.5M$25M$12.5M$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$153,400,583 · 18
By mechanism
R01$124,217,056 · 3
RF1$17,589,434 · 5
R44$5,440,815 · 3
R42$2,126,690 · 1
SB1$1,642,783 · 1
U01$1,520,864 · 1
Investigators at Cognition Therapeutics, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Largest grants
Randomized Double Blind, Placebo Controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease over 18 Months$24,533,829
R01 · FY2020 · AG
Randomized Double Blind, Placebo Controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease over 18 Months$14,619,478
R01 · FY2021 · AG
A Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Phase II Study to Evaluate the Safety and Efficacy of CT1812 in Subjects with Mild to Moderate Alzheimerʼs Disease$13,634,548
R01 · FY2021 · AG
Randomized Double Blind, Placebo Controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease over 18 Months$13,127,747
R01 · FY2024 · AG
Randomized Double Blind, Placebo Controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease over 18 Months$11,955,061
R01 · FY2025 · AG
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Subjects with Dementia with Lewy Bodies$10,764,669
R01 · FY2021 · AG
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Subjects with Dementia with Lewy Bodies$10,254,288
R01 · FY2022 · AG
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Subjects with Dementia with Lewy Bodies$8,479,107
R01 · FY2023 · AG
A Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Phase II Study to Evaluate the Safety and Efficacy of CT1812 in Subjects with Mild to Moderate Alzheimer's Disease$5,774,586
R01 · FY2020 · AG
A Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Phase II Study to Evaluate the Safety and Efficacy of CT1812 in Subjects with Mild to Moderate Alzheimer's Disease$5,735,586
R01 · FY2019 · AG
A Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Phase II Study to Evaluate the Safety and Efficacy of CT1812 in Subjects with Mild to Moderate Alzheimer's Disease$5,059,534
R01 · FY2018 · AG
A Pilot Synaptic Vesicle Glycoprotein 2A (SV2A) PET Study to Evaluate the Effect of CT1812 Treatment on Synaptic Density in Subjects with Mild to Moderate Alzheimer's Disease$4,130,741
RF1 · FY2017 · AG
A Pilot Electroencephalography (EEG) Study to Evaluate the Effect of CT1812 Treatment on Synaptic Activity in Subjects with Mild to Moderate Alzheimerʼs Disease$3,300,642
RF1 · FY2019 · AG
A Pilot CSF Catheter Study to Evaluate the Effect of CT1812 Treatment on Aβ Oligomer Clearance into CSF in Subjects with Mild to Moderate Alzheimerʼs Disease$2,527,271
RF1 · FY2017 · AG
Phase 1b first-in-patient safety trial for CT1812, a novel Alzheimerâs synaptic protection therapeutic$2,410,669
RF1 · FY2016 · AG
Phase 1 safety trial for CT1812, a novel small molecule therapeutic targeting a synaptic receptor for Abeta oligomers$2,410,669
RF1 · FY2016 · AG
A Pilot Electroencephalography (EEG) Study to Evaluate the Effect of CT1812 Treatment on Synaptic Activity in Subjects with Mild to Moderate Alzheimerʼs Disease$2,144,409
RF1 · FY2022 · AG
Human AME study of CT1812, a small molecule in phase 2 clinical trials for the treatment of Alzheimer's disease$1,642,783
SB1 · FY2021 · AG
Optimization of sigma-2 receptor modulators for the treatment of cognitive dysfunction$1,072,222
R42 · FY2019 · AG
Optimization of sigma-2 receptor modulators for the treatment of cognitive dysfunction$1,054,468
R42 · FY2018 · AG